Research & Development
Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education
5 May 2026 - US biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Monday announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia ...
Atossa Therapeutics' (Z)-endoxifen receives FDA Rare Pediatric Disease designation for McCune-Albright Syndrome
5 May 2026 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq:ATOS) announced on Monday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) ...
Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation
30 April 2026 - Swedish biosimilars developer Xbrane Biopharma AB (STO:XBRANE) said on Thursday that it has resubmitted its Biologics License Application (BLA) to the US Food and Drug Administration (...
Sprout Pharmaceuticals named one of TIME's most influential health and life sciences companies of 2026
30 April 2026 - TIME magazine has named women's health specialist Sprout Pharmaceuticals among 10 organisations globally shaping the future of health and life sciences.This recognition follows a ...
European Commission clears first pertuzumab biosimilar in Europe
29 April 2026 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Wednesday that the European Commission has approv...
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
29 April 2026 - US biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) announced on Tuesday the publication of an original research article titled 'Efficacy and Safety of Imsidolima...